[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200101932T2 - Gen terapisi-1 - Google Patents

Gen terapisi-1

Info

Publication number
TR200101932T2
TR200101932T2 TR2001/01932T TR200101932T TR200101932T2 TR 200101932 T2 TR200101932 T2 TR 200101932T2 TR 2001/01932 T TR2001/01932 T TR 2001/01932T TR 200101932 T TR200101932 T TR 200101932T TR 200101932 T2 TR200101932 T2 TR 200101932T2
Authority
TR
Turkey
Prior art keywords
gene therapy
vectors
nabqi
acetaminophen
converted
Prior art date
Application number
TR2001/01932T
Other languages
English (en)
Inventor
Davies Donald
Original Assignee
Ml Laboratories Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900009.3A external-priority patent/GB9900009D0/en
Priority claimed from GBGB9920837.3A external-priority patent/GB9920837D0/en
Application filed by Ml Laboratories Plc filed Critical Ml Laboratories Plc
Publication of TR200101932T2 publication Critical patent/TR200101932T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Burada tanimlanan bulus, tümör hücresi spesifik P450'nin metabolik aktivitesiyle NABQI'ye dönüstürüldügünde asetaminofenin sitotoksik özelliklerini kullanan bir kanser terapisi sekliyle; P450'nin tümör hücrelerine iletiminde kullanilacak vektörlerle; ve bu vektörleri içeren terapötik terkiplerle ilgilidir.
TR2001/01932T 1999-01-04 1999-12-30 Gen terapisi-1 TR200101932T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9900009.3A GB9900009D0 (en) 1999-01-04 1999-01-04 Gene therapy
GBGB9920837.3A GB9920837D0 (en) 1999-09-04 1999-09-04 Gene therapy

Publications (1)

Publication Number Publication Date
TR200101932T2 true TR200101932T2 (tr) 2001-11-21

Family

ID=26314950

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01932T TR200101932T2 (tr) 1999-01-04 1999-12-30 Gen terapisi-1

Country Status (14)

Country Link
US (1) US7091040B1 (tr)
EP (1) EP1141318B1 (tr)
JP (1) JP2002534397A (tr)
AT (1) ATE332377T1 (tr)
AU (1) AU1869900A (tr)
CA (1) CA2355859A1 (tr)
CZ (1) CZ20012362A3 (tr)
DE (1) DE69932261D1 (tr)
HU (1) HUP0105208A3 (tr)
IL (1) IL143701A0 (tr)
NO (1) NO20013306L (tr)
PL (1) PL349285A1 (tr)
TR (1) TR200101932T2 (tr)
WO (1) WO2000040271A2 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492428B1 (en) * 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US7674454B2 (en) 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
GB0405103D0 (en) * 2004-03-06 2004-04-07 Ml Lab Plc Enzyme-prodrug therapy for prosthetic joint repair
CA2556790A1 (en) * 2004-03-06 2005-09-15 Innovata Plc Enzyme-prodrug therapy for prosthetic joint repair
US20090318561A1 (en) * 2008-06-23 2009-12-24 Mutual Pharmaceutical Company, Inc. Colchicine products, method of manufacture, and methods of use
US10849981B2 (en) * 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
FR2958849A1 (fr) * 2010-04-14 2011-10-21 Boiron Medicament homeopathique a activite anti-cancereuse
US9868960B2 (en) 2013-05-10 2018-01-16 National Brain Research Centre Placental like alkaline phosphatase (PLAP) promoter mediated cell targeting
JP2021522787A (ja) * 2018-04-30 2021-09-02 オレゴン ヘルス アンド サイエンス ユニバーシティ 遺伝子治療の方法
GB201901989D0 (en) 2019-02-13 2019-04-03 Zephapharm Ltd Pharmaceutical combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760008A (en) * 1991-11-04 1998-06-02 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors
DE69730595D1 (de) * 1996-03-27 2004-10-14 Bavarian Nordic As Kvistgaard Verkapselte zellen expremierend cytochrome p450 für die aktivierung einer medikamentenvorstufe
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation

Also Published As

Publication number Publication date
WO2000040271A3 (en) 2000-11-02
NO20013306L (no) 2001-09-03
ATE332377T1 (de) 2006-07-15
CA2355859A1 (en) 2000-07-13
WO2000040271A2 (en) 2000-07-13
IL143701A0 (en) 2002-04-21
DE69932261D1 (de) 2006-08-17
HUP0105208A3 (en) 2004-08-30
EP1141318A2 (en) 2001-10-10
HUP0105208A2 (hu) 2002-04-29
AU1869900A (en) 2000-07-24
PL349285A1 (en) 2002-07-15
CZ20012362A3 (cs) 2007-05-09
NO20013306D0 (no) 2001-07-03
JP2002534397A (ja) 2002-10-15
US7091040B1 (en) 2006-08-15
EP1141318B1 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
TR200101932T2 (tr) Gen terapisi-1
IL149046A0 (en) 36p6d5: secreted tumor antigen
BR9910251A (pt) Estimulação hematopoiética
GB9415167D0 (en) Improvements relating to cancer therapy
MX2008007286A (es) Ingenieria in vivo de superficie celular.
IL148008A0 (en) Conditional immortalisation of cells
TR200000482T2 (tr) N-Aroilfenilalanin türevleri.
TR200002326T2 (tr) Bir apoptoz meydana getirmek ve/veya iltihapsal reaksiyonu azaltmak için arjinin deiminaz ile donatılmış bakteri kullanımı ve bu tür bakterileri içeren ilaç veya besin karışımları
EP1206252A4 (en) REINFORCEMENT OF THE FOLATED TARGET DIRECTNESS ON TUMOR CELLS USING POLYMERS
EP1206251A4 (en) STRENGTHENING FOLATE-MEDIATED TARGETING ON TUMOR CELLS USING NANOPARTICLES
BR0214840A (pt) Genes
TR199801395A2 (tr) Genetik olarak degistirilmis hücreler ve bunlarin kullanimlari.
EP2289940A3 (en) Treatment of metastatic disease
IL135438A (en) Pharmaceutical compositions containing styrl sulfones and some such novel styryl sulfone compounds with anticancer activity
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
CA2368653A1 (en) Z-styryl sulfone anticancer agents
AU2290000A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
PL356780A1 (en) Novel compounds
IL312192A (en) Mammalian cells containing integrated CAS9 genes to produce stable integration sites, and mammalian cells containing stable integration sites and other sites
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
PL374675A1 (en) Use of urease for inhibiting cancer cell growth
IL125795A0 (en) Retroviral vectors encoding a cytochrome p450 gene
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
WO2000040272A3 (en) P450 / acetaminophen gdept for cancer treatment